Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta
Zacks.com highlights biotech stocks, focusing on Q4 earnings and regulatory updates. Moderna beat earnings estimates, reaffirmed 2024 sales guidance, and expects RSV vaccine approval. RAPT Therapeutics faced a clinical hold due to a liver failure case. Iovance surged after FDA approval for melanoma treatment. Sarepta seeks label expansion for DMD drug. Regeneron's myeloma drug gets Priority Review.
Q4 2023 Clearside Biomedical Inc Earnings Call
Clearside Biomedical discussed its Q4 2023 financial results and corporate updates, highlighting progress in its CLS-AX clinical development program for wet AMD, including the initiation and completion of the Phase IIb trial, Odyssey. The company emphasized its leadership in suprachoroidal drug delivery technology, collaborations, and anticipated data readouts in 2024. Financial updates included a cash balance sufficient to fund operations into Q3 2025.
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates
Amylyx Pharmaceuticals' shares fell after its ALS treatment failed in a phase III study. Acadia Pharmaceuticals also saw a decline due to a failed schizophrenia treatment study. Regulus Therapeutics reported positive results for a kidney disease treatment, boosting its shares. Moderna initiated a cancer therapy study, increasing its stock value. Regeneron received FDA approval to extend its cholesterol drug's label to pediatric patients.
Causaly, an AI platform for drug discovery and biomedical research, raises $60M
Causaly, a London AI startup, raised $60M in Series B funding led by ICONIQ Growth, totaling $93M. Its platform accelerates drug discovery, reducing development time from 10-15 years to several, and is used by major pharmaceutical companies. Unlike others, Causaly focuses on providing tools for drug discovery rather than developing therapeutics.
Intellia to lay off staff, cut some early research
Intellia Therapeutics, a CRISPR specialist, will lay off 15% of its workforce, pausing some early-stage research to focus on its advanced drug candidate, NTLA-2001, for ATTR amyloidosis. Despite setbacks, including a discontinued partnership with Novartis, Intellia continues Phase 3 trials for NTLA-2001 and explores gene editing treatments with Regeneron.
Updated Odronextamab Data from Relapsed/Refractory Diffuse
Phase 2 trial results for odronextamab showed a 52% ORR and 31% CR in DLBCL patients, with durable responses. Phase 1 data indicated a 48% ORR and 30% CR post-CAR-T progression. ctDNA negativity linked to longer PFS. Odronextamab is under FDA and EMA review for R/R DLBCL and FL.
The real-world efficacy and safety of faricimab in improving visual acuity and anatomical parameters for nAMD patients
Faricimab showed improvement in visual acuity and anatomical parameters for nAMD patients, with a low incidence of treatable intraocular inflammation. Real-world data supports its efficacy and safety, especially in previously-treated patients.
Strategies for Building Greater DE&I in Rare Disease Trials
Diversity, equity, and inclusion (DE&I) in clinical trials, especially for rare diseases, face systemic barriers across strategic, protocol, site, and patient levels. Efforts to improve DE&I include inclusive trial designs, reducing patient burden, leveraging PAOs, and fostering industry collaboration. Progress requires dedicated action across the drug development ecosystem to ensure equitable access and representative trial populations.
Here's What is Driving Amgen (AMGN) Stock's Outperformance
Amgen, a leading biotech firm, excels in oncology, cardiovascular, and other health markets, with a robust pipeline and strong cash position for growth. Its key drugs and biosimilars, including Tezspire and Lumakras, are expanding through approvals and label expansions, despite some sales challenges. Biosimilars like Amjevita are pivotal for future growth.
FDA wants confirmatory trials to be underway before accelerated approvals
The FDA, led by Richard Pazdur, is tightening requirements for accelerated approvals of cancer drugs, demanding confirmatory trial plans upfront. This shift aims to reduce the time between approval and efficacy confirmation, impacting small biotechs reliant on initial approvals for funding. The policy emphasizes patient benefit over industry incentives.
© Copyright 2025. All Rights Reserved by MedPath